0
0
7/17/25 at 5:59pm
Organization
STAT
Author
Andrew Joseph
38 words
0
Comments
FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose
You are the first to view
https://www.statnews.com/2025/07/17/blenrep-advisory-committee-fda-gsk-multiple-myeloma/
Create an account
or login to join the discussion